GlassScriptPhysician profile
Mackenzie Lewis
NPI 1992301105
$4,683.01
in general payments reported to CMS, 2019-2025
21 companies · $323 in 2025
The $323 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $587 · 2022: $1,371 · 2023: $2,150 · 2024: $252 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,725.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $651.43 | 2022-2025 | Auvelity |
| Corium, LLC | $444.33 | 2021-2025 | Azstarys |
| Abbvie INC. | $418.50 | 2021-2025 | |
| Alkermes, INC. | $394.47 | 2021-2024 | Lybalvi, Aristada |
| Lundbeck LLC | $352.33 | 2021-2024 | Rexulti, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $338.27 | 2021-2024 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $314.93 | 2021-2023 | Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $299.92 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $273.09 | 2021-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $271.04 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $251.11 | 2021-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $186.03 | 2022-2023 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $122.84 | 2022-2024 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $86.21 | 2022-2023 | Belsomra |
| Idorsia Pharmaceuticals US INC | $81.48 | 2022-2023 | Quviviq |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $55.37 | 2023 | Dyanavel Xr |
| Bard Peripheral Vascular, INC. | $41.38 | 2021 | |
| Collegium Pharmaceutical, INC. | $36.82 | 2025 | Jornay Pm |
| Eisai INC. | $28.95 | 2021-2022 | |
| Noven Therapeutics, LLC | $19.13 | 2021 | |
| Bausch Health US, LLC | $15.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.